Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.

Next Previous
Trial Profile

A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Disease-modifying antirheumatics; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 23 Feb 2010 Planned number of patients changed from 98 to 138 as reported by Roche record.
  • 19 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top